Previous Close | 125.52 |
Open | 132.87 |
Bid | 132.47 x 1200 |
Ask | 132.51 x 1000 |
Day's Range | 130.11 - 133.10 |
52 Week Range | 99.14 - 133.10 |
Volume | |
Avg. Volume | 8,735,054 |
Market Cap | 333.675B |
Beta (5Y Monthly) | 0.38 |
PE Ratio (TTM) | 941.07 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 3.08 (2.34%) |
Ex-Dividend Date | Mar 14, 2024 |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for MRK
The Food and Drug Administration has approved Winrevair, Merck's (MRK) latest drug to treat pulmonary arterial hypertension, a lung condition. Investors have been anxiously awaiting the approval as the company is set to lose its patent for Keytruda. The drug will help to reduce the risk of death and worsening events in patients by 84%. Yahoo Finance's Anjalee Khemlani joins The Morning Brief to discuss how the treatment could offer a potential path to the upside for Merck. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. Editor's Note: This article was written by Gabriel Roy
U.S. stocks were higher on Wednesday, with the Dow leading gains and the S&P 500 setting a closing record, paced drugmaker Merck, while investors looked towards the next piece of inflation data and Federal Reserve commentary for signals on the rate path. Merck & Co advanced 4.96% as the best performer on the Dow after the U.S. Food and Drug Administration approved its therapy for adults suffering from a rare lung condition.